- Home
- IBIO vs MCRB Comparison
IBIO vs MCRB Comparison
Compare IBIO & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | MCRB |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.0M | 71.0M |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IBIO | MCRB |
|---|---|---|
| Price | $1.65 | $6.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $4.75 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 777.5K | 84.9K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $5.31 |
| 52 Week High | $3.82 | $29.98 |
Technical Indicators
Market Signals| Indicator | IBIO | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 51.83 |
| Support Level | $1.43 | $6.56 |
| Resistance Level | $1.80 | $9.53 |
| Average True Range (ATR) | 0.11 | 0.71 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 45.68 | 75.66 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.